You are here

Our People

We work with leading research scientists to identify and nurture research that has strong clinical and commercial potential. Projects with translational potential are guided through the process by one of our experienced Business Development Managers. We build strong personal relationships with our partners and keep lines of communication open and simple to ensure the free flow of information and ideas. This ensures all potential opportunities are capitalised on as innovatively and efficiently as possible.

Cancer Research Technology Board Open

Peter Chambré, Chairman Mr. Peter A. Chambre is Chairman of CRT since October 2011. He is Independent Non-Executive Director of BTG Plc., since September 2006 and Chairman of Xellia Pharmaceuticals AS, OneMed AB and 7TM Pharma A/S. He is also a non-executive director of Spectris plc, the precision instrumentation and controls company. Peter was Chief Executive Officer of Cambridge Antibody Technology Group plc from 2002 until its acquisition by AstraZeneca plc in 2006. Previously he was Chief Operating Officer of Celera Genomics Group and Chief Executive of Bespak plc.


 

Dr Andy Richards CBE Dr Andy Richards CBE is a biotechnology entrepreneur and investor. His current business activity focuses on growing successful biotechnology and healthcare technology companies. He is currently Chairman of Ixicio plc, Congenica Limited, Novacta Biosystems Limited, Abcodia Limited and Cambridge Temperature Concepts Limited, as well as a director of Arecor Limited, Ieso Health Limited (formerly PsychologyOnline.co.uk Limited) and Babraham Bioscience Technologies Limited. Andy is also a director of Cambridge University Health Trust and an adviser to Vectura Group plc. He was a founder of Chiroscience, one of Europe’s most successful biotech companies, and an executive director through to the merger with Celltech in 1999. Since that time he has been founding, investing in and directing new UK healthcare and life science companies. Andy joined the board of CRT is August 2003. He is a graduate of Cambridge University with a PhD in Chemistry.


Iain Foulkes, PhD Iain is Cancer Research UK's Executive Director of Research and Innovation and CEO of Cancer Research Technology. Iain is responsible for helping to shape the long-term direction of the Charity and to ensure we have effective strategies to meet our ambitious goals. Iain began his career as a research scientist, completing his PhD at the Cancer Research UK Beatson Institute. He then became a science writer and medical journalist, before moving into Policy and Communications at the Imperial Cancer Research Fund (ICRF). During his time at ICRF, he worked closely with Sir Paul Nurse, who at that time was Chief Executive, helping to drive through the merger of ICRF and Cancer Research Campaign to become Cancer Research UK. From January 2003, he was Director of Strategic Development in Fundraising and Supporter Marketing, and has supported the early-stage development of UK Centre for Medical Research and Innovation working with Sir Paul Nurse.


Michelle Mitchell OBE Michelle is Chief Executive of Cancer Research UK, appointed in 2018. 


 

Deborah Harland Deborah has extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during her more than 25 year tenure in the pharmaceutical industry. She joined SR One, the corporate venture capital arm of GlaxoSmithKline, in 2005 to establish the firm’s European investment office. Deborah is currently a member of the Board of Directors of Asceneuron, Mission Therapeutics, Bicycle Therapeutics, f-star, Atopix Therapeutics and VH Squared. She was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange, 2007), Pharmakodex Limited (sold to Orexo) and Syntaxin Limited (sold to Ipsen) and an observer on the Boards of Ablynx (IPO, Euronext Brussels 2007) and 7TM Pharma. Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from the University of London, and her MBA from Henley Management College.


Andrew Waldron (Company Secretary)


Tony Hickson BSc, MBA, CLP, RTTP Tony is the Chief Business Officer for Cancer Research UK. He leads the Commercial Partnerships team responsible for the commercialisation of IP from CRUK funded projects, new start-up creation, licences and corporate alliances. Prior to this Tony was the Managing Director of Imperial Innovations Ltd, responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Tony has sat on the Executive Committee of IP Group and spent 5 years as an executive director on the board of Touchstone Innovations PLC, a company listed on the London Stock exchange investing in deep science projects from UK universities. Prior to joining Imperial Innovations, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group R&D, Murex Biotech, Abbott Laboratories and Kalibrant Limited. He has acted as a board director or observer for a number of start-up companies including Polytherics (now Abzena), Catapult Therapy TCR, Zihipp and Precision Robotics, and was instrumental in the creation & development of companies such as Thiakis (sold to Wyeth/Pfizer in 2008), Respivert (sold to J&J in 2010), Circassia (listed on LSE in 2014), EMcision (sold to Boston Scientific in 2018) and Cell Medica (in advanced clinical studies). Tony has sat on the IP boards of two European Institutes of Technology (Healthcare and Climate Change), is a member of the BBSRC industry advisory panel and a board director of PraxisUnico. He has a diploma in company direction from the Institute of Directors and is a Certified Licensing Professional.

 

Therapeutic Discovery Laboratories Open

Business Development Open

 

Dr Phil Masterson, Associate Director.  Phil has been working as Associate Director of the Commercial Partnerships team since June 2011. Phil has a BSc in Cell Biology from the University of Essex, and a PhD in Virology from the University of Cambridge. After a post-doc position at the National Institute for Medical Research (NIMR) in London, Phil spent a number of years managing R&D programmes in the biotech industry. He moved into technology transfer in 2003 when he joined Cancer Research Technology, the predecessor of CRUK's Commercial Partnerships team. Since that time he has built up extensive experience of managing and commercialising healthcare technologies from academic origins.


Dr Laura Fletcher, Associate Director. Laura obtained her first degree in Biochemistry from the University at Bristol and, after a one year sabbatical at the University of Pennsylvania, returned to Bristol to take up her PhD in insulin signalling and resistance. Her focus during this time was on cell biology and time-lapse confocal microspcopy. Shortly after completing her PhD in 2001, Laura was the co-founder of a small molecule drug discovery company called ProXara, where she spent the following five years developing fluorescent cellular screens focussed on identifying inhibitors of protein localisation events for various cancer targets. During this time she also managed the associated patent portfolio and was involved in seed fund raising and business plan development. Laura joined Cancer Research Technology, the predecessor of CRUK's Commercial Partnerships team, in summer 2006, and in June 2011 was promoted to Associate Director. 


 Dr Angus Lauder, Associate Director. After obtaining a BSc in Molecular Biology from the University of Edinburgh, Angus moved to London to complete a PhD at the Institute of Cancer Research working on signal transduction and gene expression of the oncogene c-Myb. He then undertook post-doctoral research studies at the MRC Laboratory of Molecular Biology in Cambridge working on models of leukaemia and the roles of cytokines in controlling leukaemia development. Angus has worked for CRUK's Commercial Partnerships team (joining when it was Cancer Research Technology) for twelve years during which time he has worked on a wide range of therapeutic projects, research technologies and biomarker opportunities. During this time he has gained in-depth experience of a broad set of translational and commercialisation models including licensing, industry-academia alliances and formation of a number of spin-out companies. Angus currently manages a team of five business managers and provides strategic input and advice to the team to facilitate translation of technologies from a range of university partners using many different commercialisation routes and models.

Read more about our services

USA Office Open

 Andrea Schievella, President of our US Office Andrea has been focused on partnering early stage life sciences technologies for over 15 years. Since joining the organisation she has been building relationships between CRUK and the biotech/pharma industry and venture firms throughout the US. Prior to this role, Andrea was at MIT's Technology Licensing Office, where she regularly engaged with both established and startup companies to license technology from MIT, the Whitehead Institute and Lincoln Laboratory. Previous to that, Andrea was one of the first ten employees at Variagenics, a personalized medicine startup out of MIT. Initially hired as a scientist, after three years Andrea transitioned into business development, where she focused on alliance development in the US and Europe for a further three years until the company was acquired. Andrea received her undergraduate degree in Biology at MIT and her PhD from Harvard, followed by a three-year postdoctoral fellowship with Genetics Institute's Small Molecule Drug Discovery group.  


Bob Bondaryk

 

View our projects

Clinical Partnerships Open

Research tools - Ximbio Open

Chief Business Officer Open

Tony Hickson BSc, MBA, CLP, RTTP Tony is the Chief Business Officer for Cancer Research UK. He leads the Commercial Partnerships team responsible for the commercialisation of IP from CRUK funded projects, new start-up creation, licences and corporate alliances. Prior to this Tony was the Managing Director of Imperial Innovations Ltd, responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Tony has sat on the Executive Committee of IP Group and spent 5 years as an executive director on the board of Touchstone Innovations PLC, a company listed on the London Stock exchange investing in deep science projects from UK universities. Prior to joining Imperial Innovations, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group R&D, Murex Biotech, Abbott Laboratories and Kalibrant Limited. He has acted as a board director or observer for a number of start-up companies including Polytherics (now Abzena), Catapult Therapy TCR, Zihipp and Precision Robotics, and was instrumental in the creation & development of companies such as Thiakis (sold to Wyeth/Pfizer in 2008), Respivert (sold to J&J in 2010), Circassia (listed on LSE in 2014), EMcision (sold to Boston Scientific in 2018) and Cell Medica (in advanced clinical studies). Tony has sat on the IP boards of two European Institutes of Technology (Healthcare and Climate Change), is a member of the BBSRC industry advisory panel and a board director of PraxisUnico. He has a diploma in company direction from the Institute of Directors and is a Certified Licensing Professional.

  • Peter Chambré, Chairman Mr. Peter A. Chambre is Chairman of CRT since October 2011. He is Independent Non-Executive Director of BTG Plc., since September 2006 and Chairman of Xellia Pharmaceuticals AS, OneMed AB and 7TM Pharma A/S. He is also a non-executive director of Spectris plc, the precision instrumentation and controls company. Peter was Chief Executive Officer of Cambridge Antibody Technology Group plc from 2002 until its acquisition by AstraZeneca plc in 2006. Previously he was Chief Operating Officer of Celera Genomics Group and Chief Executive of Bespak plc.


     

    Dr Andy Richards CBE Dr Andy Richards CBE is a biotechnology entrepreneur and investor. His current business activity focuses on growing successful biotechnology and healthcare technology companies. He is currently Chairman of Ixicio plc, Congenica Limited, Novacta Biosystems Limited, Abcodia Limited and Cambridge Temperature Concepts Limited, as well as a director of Arecor Limited, Ieso Health Limited (formerly PsychologyOnline.co.uk Limited) and Babraham Bioscience Technologies Limited. Andy is also a director of Cambridge University Health Trust and an adviser to Vectura Group plc. He was a founder of Chiroscience, one of Europe’s most successful biotech companies, and an executive director through to the merger with Celltech in 1999. Since that time he has been founding, investing in and directing new UK healthcare and life science companies. Andy joined the board of CRT is August 2003. He is a graduate of Cambridge University with a PhD in Chemistry.


    Iain Foulkes, PhD Iain is Cancer Research UK's Executive Director of Research and Innovation and CEO of Cancer Research Technology. Iain is responsible for helping to shape the long-term direction of the Charity and to ensure we have effective strategies to meet our ambitious goals. Iain began his career as a research scientist, completing his PhD at the Cancer Research UK Beatson Institute. He then became a science writer and medical journalist, before moving into Policy and Communications at the Imperial Cancer Research Fund (ICRF). During his time at ICRF, he worked closely with Sir Paul Nurse, who at that time was Chief Executive, helping to drive through the merger of ICRF and Cancer Research Campaign to become Cancer Research UK. From January 2003, he was Director of Strategic Development in Fundraising and Supporter Marketing, and has supported the early-stage development of UK Centre for Medical Research and Innovation working with Sir Paul Nurse.


    Michelle Mitchell OBE Michelle is Chief Executive of Cancer Research UK, appointed in 2018. 


     

    Deborah Harland Deborah has extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during her more than 25 year tenure in the pharmaceutical industry. She joined SR One, the corporate venture capital arm of GlaxoSmithKline, in 2005 to establish the firm’s European investment office. Deborah is currently a member of the Board of Directors of Asceneuron, Mission Therapeutics, Bicycle Therapeutics, f-star, Atopix Therapeutics and VH Squared. She was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange, 2007), Pharmakodex Limited (sold to Orexo) and Syntaxin Limited (sold to Ipsen) and an observer on the Boards of Ablynx (IPO, Euronext Brussels 2007) and 7TM Pharma. Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from the University of London, and her MBA from Henley Management College.


    Andrew Waldron (Company Secretary)


    Tony Hickson BSc, MBA, CLP, RTTP Tony is the Chief Business Officer for Cancer Research UK. He leads the Commercial Partnerships team responsible for the commercialisation of IP from CRUK funded projects, new start-up creation, licences and corporate alliances. Prior to this Tony was the Managing Director of Imperial Innovations Ltd, responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Tony has sat on the Executive Committee of IP Group and spent 5 years as an executive director on the board of Touchstone Innovations PLC, a company listed on the London Stock exchange investing in deep science projects from UK universities. Prior to joining Imperial Innovations, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group R&D, Murex Biotech, Abbott Laboratories and Kalibrant Limited. He has acted as a board director or observer for a number of start-up companies including Polytherics (now Abzena), Catapult Therapy TCR, Zihipp and Precision Robotics, and was instrumental in the creation & development of companies such as Thiakis (sold to Wyeth/Pfizer in 2008), Respivert (sold to J&J in 2010), Circassia (listed on LSE in 2014), EMcision (sold to Boston Scientific in 2018) and Cell Medica (in advanced clinical studies). Tony has sat on the IP boards of two European Institutes of Technology (Healthcare and Climate Change), is a member of the BBSRC industry advisory panel and a board director of PraxisUnico. He has a diploma in company direction from the Institute of Directors and is a Certified Licensing Professional.

     
  •  

    Dr Phil Masterson, Associate Director.  Phil has been working as Associate Director of the Commercial Partnerships team since June 2011. Phil has a BSc in Cell Biology from the University of Essex, and a PhD in Virology from the University of Cambridge. After a post-doc position at the National Institute for Medical Research (NIMR) in London, Phil spent a number of years managing R&D programmes in the biotech industry. He moved into technology transfer in 2003 when he joined Cancer Research Technology, the predecessor of CRUK's Commercial Partnerships team. Since that time he has built up extensive experience of managing and commercialising healthcare technologies from academic origins.


    Dr Laura Fletcher, Associate Director. Laura obtained her first degree in Biochemistry from the University at Bristol and, after a one year sabbatical at the University of Pennsylvania, returned to Bristol to take up her PhD in insulin signalling and resistance. Her focus during this time was on cell biology and time-lapse confocal microspcopy. Shortly after completing her PhD in 2001, Laura was the co-founder of a small molecule drug discovery company called ProXara, where she spent the following five years developing fluorescent cellular screens focussed on identifying inhibitors of protein localisation events for various cancer targets. During this time she also managed the associated patent portfolio and was involved in seed fund raising and business plan development. Laura joined Cancer Research Technology, the predecessor of CRUK's Commercial Partnerships team, in summer 2006, and in June 2011 was promoted to Associate Director. 


     Dr Angus Lauder, Associate Director. After obtaining a BSc in Molecular Biology from the University of Edinburgh, Angus moved to London to complete a PhD at the Institute of Cancer Research working on signal transduction and gene expression of the oncogene c-Myb. He then undertook post-doctoral research studies at the MRC Laboratory of Molecular Biology in Cambridge working on models of leukaemia and the roles of cytokines in controlling leukaemia development. Angus has worked for CRUK's Commercial Partnerships team (joining when it was Cancer Research Technology) for twelve years during which time he has worked on a wide range of therapeutic projects, research technologies and biomarker opportunities. During this time he has gained in-depth experience of a broad set of translational and commercialisation models including licensing, industry-academia alliances and formation of a number of spin-out companies. Angus currently manages a team of five business managers and provides strategic input and advice to the team to facilitate translation of technologies from a range of university partners using many different commercialisation routes and models.

    Read more about our services

  •  Andrea Schievella, President of our US Office Andrea has been focused on partnering early stage life sciences technologies for over 15 years. Since joining the organisation she has been building relationships between CRUK and the biotech/pharma industry and venture firms throughout the US. Prior to this role, Andrea was at MIT's Technology Licensing Office, where she regularly engaged with both established and startup companies to license technology from MIT, the Whitehead Institute and Lincoln Laboratory. Previous to that, Andrea was one of the first ten employees at Variagenics, a personalized medicine startup out of MIT. Initially hired as a scientist, after three years Andrea transitioned into business development, where she focused on alliance development in the US and Europe for a further three years until the company was acquired. Andrea received her undergraduate degree in Biology at MIT and her PhD from Harvard, followed by a three-year postdoctoral fellowship with Genetics Institute's Small Molecule Drug Discovery group.  


    Bob Bondaryk

     

    View our projects

  • Tony Hickson BSc, MBA, CLP, RTTP Tony is the Chief Business Officer for Cancer Research UK. He leads the Commercial Partnerships team responsible for the commercialisation of IP from CRUK funded projects, new start-up creation, licences and corporate alliances. Prior to this Tony was the Managing Director of Imperial Innovations Ltd, responsible for intellectual property sourcing, licensing and spin-out creation for technologies arising from Imperial College London. Tony has sat on the Executive Committee of IP Group and spent 5 years as an executive director on the board of Touchstone Innovations PLC, a company listed on the London Stock exchange investing in deep science projects from UK universities. Prior to joining Imperial Innovations, Tony had acquired 15 years of commercial and business development experience in bioscience companies including Wellcome Group R&D, Murex Biotech, Abbott Laboratories and Kalibrant Limited. He has acted as a board director or observer for a number of start-up companies including Polytherics (now Abzena), Catapult Therapy TCR, Zihipp and Precision Robotics, and was instrumental in the creation & development of companies such as Thiakis (sold to Wyeth/Pfizer in 2008), Respivert (sold to J&J in 2010), Circassia (listed on LSE in 2014), EMcision (sold to Boston Scientific in 2018) and Cell Medica (in advanced clinical studies). Tony has sat on the IP boards of two European Institutes of Technology (Healthcare and Climate Change), is a member of the BBSRC industry advisory panel and a board director of PraxisUnico. He has a diploma in company direction from the Institute of Directors and is a Certified Licensing Professional.